Price
Target price
€37.00
€37.00
3.910%
1.4
3.910%
€84.74
31.05.24 / Tradegate
WKN: A1XCY0 / Symbol: RARE / Name: Ultragenyx / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Ultragenyx Pharmaceutical Inc. Stock
A very strong showing by Ultragenyx Pharmaceutical Inc. today, with an increase of €1.40 (3.910%) compared to yesterday's price.
The stock is one of the favorites of our community with 21 Buy predictions and 1 Sell predictions.
Based on the current price of 37.0 € the target price of 84 € shows a potential of 127.03% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 3.910% | -1.070% | -10.194% | -19.913% | -15.138% | -55.689% | -28.791% |
| Ironwood Pharmaceuticals | -0.900% | 0.917% | -24.138% | -46.078% | -46.078% | -41.489% | - |
| Novocure Ltd | -0.580% | -4.920% | 76.819% | -69.807% | 42.137% | -87.839% | - |
| Iovance Biotherapeutics Inc. | -0.550% | -11.212% | -25.833% | 0.392% | 4.867% | -45.918% | - |
Comments
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Bank of America Co. from $83.00 to $76.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Cantor Fitzgerald from $107.00 to $115.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Stifel Nicolaus from $124.00 to $127.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
